Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Net Change in Cash
Inhibrx Inc
Net Change in Cash Peer Comparison
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibrx Inc
NASDAQ:INBX
|
Net Change in Cash
$4.1m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
$11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$218m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$21.9B
|
CAGR 3-Years
-140%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$126.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Inhibrx Inc's Net Change in Cash?
Net Change in Cash
4.1m
USD
Based on the financial report for Dec 31, 2023, Inhibrx Inc's Net Change in Cash amounts to 4.1m USD.
What is Inhibrx Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
-67%
Over the last year, the Net Change in Cash growth was -97%. The average annual Net Change in Cash growth rates for Inhibrx Inc have been -67% over the past three years .